NasdaqGM - Delayed Quote • USD
IN8bio, Inc. (INAB)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 6:27 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 4 |
| Avg. Estimate | -0.17 | -0.15 | -0.65 | -0.63 |
| Low Estimate | -0.21 | -0.2 | -0.75 | -0.92 |
| High Estimate | -0.15 | -0.11 | -0.58 | -0.45 |
| Year Ago EPS | -0.27 | -0.23 | -1 | -0.65 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.27 | -0.24 | -0.15 | -0.18 |
| EPS Actual | -0.27 | -0.23 | -0.21 | -0.2 |
| Difference | 0 | 0.01 | -0.06 | -0.02 |
| Surprise % | 0.00% | 4.20% | -40.00% | -11.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.17 | -0.15 | -0.65 | -0.63 |
| 7 Days Ago | -0.17 | -0.15 | -0.65 | -0.63 |
| 30 Days Ago | -0.17 | -0.16 | -0.65 | -0.57 |
| 60 Days Ago | -0.18 | -0.16 | -0.68 | -0.57 |
| 90 Days Ago | -0.17 | -0.16 | -0.67 | -0.57 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | INAB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 37.00% | -- | -- | 8.30% |
| Next Qtr. | 34.80% | -- | -- | 10.70% |
| Current Year | 35.00% | -- | -- | 4.90% |
| Next Year | 3.10% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.23% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 6/4/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/10/2024 |
| Initiated | Laidlaw & Co.: Buy | 3/18/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/15/2024 |
| Initiated | JonesTrading: Buy | 3/13/2024 |
Related Tickers
CGTX Cognition Therapeutics, Inc.
1.9500
+5.98%
ELEV Elevation Oncology, Inc.
3.5300
-4.08%
CADL Candel Therapeutics, Inc.
7.15
+0.42%
ZVSA ZyVersa Therapeutics, Inc.
4.4100
-6.96%
XLO Xilio Therapeutics, Inc.
1.0500
+2.94%
XCUR Exicure, Inc.
0.3961
-16.35%
TCBP TC Biopharm (Holdings) Plc
1.0800
-7.69%
ALRN Aileron Therapeutics, Inc.
3.2400
-1.52%
REPL Replimune Group, Inc.
7.90
+11.11%
MNPR Monopar Therapeutics Inc.
0.8110
-12.70%